Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy

Malathi, S.; Sisila, Valappil; Singaravel, V.; Venkatesan, Nandakumar; Pakrudheen, Iqbal; Dhanaraj, R.; Ayyadurai, Niraikulam; Bhuvarahamurthy, V.; Kalkura, S. Narayana

doi:10.1039/d3ma00328k

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vesicular Nanosystem as a Promising Platform for the Management of Cancer

Kamel,

Darwish,

Youness

et al. 2024

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Vesicular Nanosystem as a Promising Platform for the Management of Cancer

Kamel,

Darwish,

Youness

et al. 2024

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Chemical modifications of cellulose nanoparticles for anticancer applications: perspective since 2020

Ganie,

Dar,

Rather

et al. 2024

Cellulose

View full text Add to dashboard Cite

Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells

Ahmadi,

Seyedabadi,

Ebrahimnejad

et al. 2024

AAPS PharmSciTech

View full text Add to dashboard Cite

To overcome the challenges associated with the co-delivery of AuNPs (gold nanoparticles) and miRNA as an anti-breast cancer combination therapy, niosomal systems were developed using Span 60, cholesterol, and a cationic lipid (CTAB), and the formulations were optimized using Box-Behnken experimental design. The niosomal formulations with the smallest size were selected for further optimization of size, surface charge, entrapment efficiency, and stability. To achieve this, AuNPs and DSPE-PEG2000 (2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000)were added to the formulation. The optimized niosomal formulation could effectively encapsulate AuNPs with an entrapment efficiency of 34.49% ± 0.84 and a spherical particle size of 153.6 ± 4.62 nm. The incorporation of PEG and CTAB led to notable enhancements in the overall characteristics of the delivery system. To evaluate the effectiveness of the combination therapy, various assessments such as cytotoxicity, apoptosis, and gene expression properties were conducted. The results demonstrated that the combination delivery using the new C-PEG-Nio-AuNPs (cationic pegylated niosomal gold nanoparticles) system and miRNA had the lowest IC50, the highest apoptosis rate, and the most significant upregulation of miRNA and BAX/BCL2 expression in MCF-7 cell growth. In conclusion, this innovative co-delivery approach represents a promising breakthrough in the development of therapeutic agents for breast cancer treatment. By combining multiple therapeutic agents within a single delivery system, this method has the potential to enhance treatment efficacy, reduce side effects, and improve patient outcomes. Graphical Abstract

show abstract

Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy

Abstract: Breast cancer is one of the most frequently diagnosed cancers in women, and its current treatment modalities are limited by its non-specificity and adverse side effects. We evaluated the efficacy...

Cited by 3 publications

References 74 publications

Vesicular Nanosystem as a Promising Platform for the Management of Cancer

Vesicular Nanosystem as a Promising Platform for the Management of Cancer

Chemical modifications of cellulose nanoparticles for anticancer applications: perspective since 2020

Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells

Contact Info

Product

Resources

About